Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 18Opdivo

02 1Opdivo (Domestic + Overseas)

03 3Opdualag

PharmaCompass

01

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

02

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

03

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

Brand Name : Opdivo

arrow
OTS 2025
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 907

2019 Revenue in Millions : 827

Growth (%) : 10

blank

04

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

Brand Name : Opdivo

arrow
OTS 2025
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 908

2020 Revenue in Millions : 870

Growth (%) : 12

blank

05

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

06

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

07

Brand Name : Opdualag

Nivolumab

arrow
OTS 2025
Not Confirmed

Brand Name : Opdualag

arrow
OTS 2025
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 252

2021 Revenue in Millions : 0

Growth (%) : New Launch in 2022

blank

08

Brand Name : Opdualag

Nivolumab, Relatlimab-rmbw

arrow
OTS 2025
Not Confirmed

Brand Name : Opdualag

arrow
OTS 2025
Not Confirmed

Nivolumab, Relatlimab-rmbw

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 627

2022 Revenue in Millions : 252

Growth (%) : 149

blank

09

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed

10

Brand Name : Opdivo

Nivolumab

arrow
OTS 2025
Not Confirmed